Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Despite barriers to patients' access to neurovascular treatments, particularly in the underpenetrated Chinese and Indian markets, improving healthcare infrastructure, growing demand, and clinical data supporting the endovascular approach over surgical interventions for treating neurovascular diseases will support procedure volume growth in Asia Pacific countries, resulting in strong market growth through 2027.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for Neurovascular devices in Asia Pacific across a 10-year period.
The neurovascular device markets in India and China are underpenetrated compared to the Australian and South Korean markets.
What are the factors responsible for low penetration in India and China?
How will recent efforts to improve health care infrastructure in these countries affect the adoption of neurovascular devices?
What strategies will competitors use in these markets to gain revenues?
Clinical data supporting the effectiveness of neurovascular thrombectomy procedures for the treatment of ischemic stroke will fuel this market segment.
How much growth is expected in this market segment in the Asia Pacific region?
How will the uptake of these devices vary by country?
What impact have recent product launches had on the market for neurovascular thrombectomy devices?
There is high growth potential for the Asia Pacific neurovascular angioplasty device market due to the prevalence of ICAD in this region.
What factors are driving and limiting growth in neurovascular angioplasty device adoption?
What was the impact of the SAMMPRIS trial in Asia Pacific countries?
Which companies are leading the market and what has contributed to their success?
Already a Client? Log in to access this report.
Sangeetha Iyer is an analyst within the Cardiovascular Medtech Insights team at Decision Resource Group, specializing in structural heart closure and vascular access device markerts across the Asia Pacific region, as well as medical device pricing and regulations in China and Japan. Sangeetha has represnted India at the European Society of Cardiology confrerence in Greece(2016) and Sweden(2017), where her research poster was awarded the top prize. Sangeetha holds a Doctor of Pharmacy degree from the Manipal Academy of Higher Education. Follow Sangeetha on twitter: @Slyer_DRG